Hasil Pencarian  ::  Simpan CSV :: Kembali

Abstrak :
Objective: Cancer is a disease that gets serious attention in the medical world. This is due to the ever increasing number of patients and there has been no effective way to treat. Cancer cells have telomerase activity is relatively high compared to normal cells, so the cancer cells have the ability to continue to proliferate. Cancer cells undergo uncontrolled mitosis and have high telomerase activity compared to cells normal. Telomerase is an enzyme responsible for telomere length, a segment of DNA that is the tip of chromosomes in eukaryotic cells. Telomeres are associated with the process of aging and carcinogenesis. The purpose of this study was to determine the expression of telomerase in some cells such as breast cancer, cervical cancer, and lung cancer. Methods: The research method is experimental studies in several cancer cell cultures in the form of cell line. Cancer cells used were: HeLa (cervical cancer), MCF7 and T47D (breast cancer), WiDr (lung cancer), and Raji (lymphoma) with culture medium RPMI, DMEM, and M199. Vero cells is used (fibroblast cells) as a control (normal cells). Expression of telomerase enzyme was measured by the Immunohystochemistry (IHC) method. Results: The results showed that the cancer cells have activity/higher telomerase expression were highly significant (p<0.01) compared to normal cells (Vero cells). Similarly, the expression of telomerase in HeLa versus WiDr, WiDr versus T47D, T47D versus Raji, and Raji versus MCF7 also showed highly significant differences (p < 0.01). Telomerase expression between cancer cells that showed significant difference (HeLa cells versus Raji cells; HeLa cells versus MCF7 cell; T47D cells versus MCF7 cells) (p < 0.05). No significant difference was found in the group of HeLa cells versus T47D, WiDr versus Raji cells, and WiDr versus MCF7. Conclusions: It was concluded, that the cancer cells have telomerase expression of specific and different from each other, depending on the type of cell. T47D breast cancer cells have telomerase expression of the highest, followed by cervical cancer cells (HeLa). Lung cancer cells (WiDr) with cell lymphoma (Raji) has almost the same expression and both have lower expression.;

Abstrak :
Objective: Cancer is a disease that gets serious attention in the medical world. This is due to the ever increasing number of patients and there has been no effective way to treat. Cancer cells have telomerase activity is relatively high compared to normal cells, so the cancer cells have the ability to continue to proliferate. Cancer cells undergo uncontrolled mitosis and have high telomerase activity compared to cells normal. Telomerase is an enzyme responsible for telomere length, a segment of DNA that is the tip of chromosomes in eukaryotic cells. Telomeres are associated with the process of aging and carcinogenesis. The purpose of this study was to determine the expression of telomerase in some cells such as breast cancer, cervical cancer, and lung cancer. Methods: The research method is experimental studies in several cancer cell cultures in the form of cell line. Cancer cells used were: HeLa (cervical cancer), MCF7 and T47D (breast cancer), WiDr (lung cancer), and Raji (lymphoma) with culture medium RPMI, DMEM, and M199. Vero cells is used (fibroblast cells) as a control (normal cells). Expression of telomerase enzyme was measured by the Immunohystochemistry (IHC) method. Results: The results showed that the cancer cells have activity/higher telomerase expression were highly significant (p < 0.01) compared to normal cells (Vero cells). Similarly, the expression of telomerase in HeLa versus WiDr, WiDr versus T47D, T47D versus Raji, and Raji versus MCF7 also showed highly significant differences (p < 0.01). Telomerase expression between cancer cells that showed significant difference (HeLa cells versus Raji cells; HeLa cells versus MCF7 cell; T47D cells versus MCF7 cells) (p < 0.05). No significant difference was found in the group of HeLa cells versus T47D, WiDr versus Raji cells, and WiDr versus MCF7. Conclusions: It was concluded, that the cancer cells have telomerase expression of specific and different from each other, depending on the type of cell. T47D breast cancer cells have telomerase expression of the highest, followed by cervical cancer cells (HeLa). Lung cancer cells (WiDr) with cell lymphoma (Raji) has almost the same expression and both have lower expression.

Abstrak :
Pada tahun 2020, PT Pertamina Bina Medika IHC (PERTAMEDIKA IHC) mengeluarkan Buku Formularium Obat PERTAMEDIKA IHC yang terdapat Peraturan Direktur Nomor Prt–2099/A00000/2020-S0 tentang Formularium Obat PERTAMEDIKA IHC (FOPI) Tahun 2021 untuk membuat dan memberlakukan standarisasi FOPI di lingkungan PERTAMEDIKA IHC dengan ketentuan semua rumah sakit yang berada di lingkungan PERTAMEDIKA dan RS IHC Member wajib menggunakan FOPI dan tidak diperkenankan adanya Formularium atau Daftar Standar Obat lain. Maka dari itu, perlu adanya penyesuaian daftar obat dalam Formularium RS UI dengan FOPI. Kegiatan dilakukan dengan pengolahan dua buah data berupa master obat Formularium RS UI serta FOPI dalam bentuk format excel dengan Formularium RS UI sebagai master data. Lalu, dilanjutkan perhitungan persentase dari masing-masing kategori obat yang tersubtitusi, tidak perlu subtitusi atau tidak tersubtitusi. Diperoleh jumlah obat Formularium RS UI yang dapat disubtitusi ke FOPI sejumlah total 442 obat dengan persentase total 18,53%. Jumlah obat yang masuk dalam kategori “Tidak Perlu Subtitusi” sebanyak 1102 obat dengan total persentase sebesar 47,71%. Sedangkan, jumlah obat yang tidak bisa disubtitusi adalah sejumlah 383 obat dengan persentase total 16,58%. Jumlah obat non FOPI adalah sejumlah 383 obat dengan persentase 16,58%. Obat yang tidak tersubtitusi perlu dilakukan pengkajian kembali antara Farmasi dengan Pelayanan Medik/KFT/KSM terkait untuk mendukung efisiensi dan efektivitas formularium RS UI. ...... To create and implement FOPI standardization in Indonesia, PT Pertamina Bina Medika IHC (PERTAMEDIKA IHC) released the PERTAMEDIKA IHC Drug Formulary Book in 2020. This publication includes Director Regulation Number Prt-2099/A00000/2020-S0 addressing the 2021 PERTAMEDIKA IHC (FOPI) Drug Formulary. PERTAMEDIKA IHC environment on the condition that all hospitals within PERTAMEDIKA and IHC Member Hospitals must use FOPI and that no Formulary or other Standard List of Drugs is permitted. Consequently, it is required to update the UI Hospital Formulary's medicine list with FOPI. The task involved processing two sets of data, the UI Hospital's master drug formulary and FOPI's FOPI in excel format, with the UI RS Formulary serving as the master data. The percentage of each drug category that is substituted, whether a substitution is required or not, should then be calculated. There are 442 different medications in the UI Hospital Formulary that can replace FOPI, with a total substitution percentage of 18.53%. 1102 medicines, or a total proportion of 47.71, fall under the "No Need Substitution" category. 383 medicines, or a total percentage of 16.58%, cannot be substituted, however. There are 383 non-FOPI medications, with a proportion of 16.58%. To promote the efficacy and efficiency of the UI Hospital formulary, drugs that cannot be substituted must be discussed between the Pharmacy and the relevant Medical Services/KFT/KSM.

Abstrak :
Analisis risiko pada aktivitas pekerjaan WBS Green Retrofitting berbasis GBCI dan Permen PUPR Nomor 21 Tahun 2021 pada Aspek EEC dan Aspek IHC masih belum dilakukan. Pelaksanaan Green Retrofitting merupakan konsep yang relatif baru di negara berkembang, sehingga sehingga risiko proyek Green Retrofitting kemungkinan lebih besar dan kompleks dibandingkan risiko pada proyek konvensional. Penelitian bertujuan untuk mengidentifikasi pengaruh estimasi biaya pada pekerjaan Green Retrofitting yang dipengaruhi oleh faktor risiko yang dominan. Penelitian menggunakan metode regresi linier, melalui aplikasi SPSS. Diketahui beberapa risiko dominan yang berpengaruh terhadap biaya Green Retrofitting adalah kelangkaan material serta fluktuasi harga material Green Products. ......Risk analysis on green retrofitting WBS work activities based on GBCI and PUPR Regulation Number 21 of 2021 on EEC and IHC aspects has not yet been carried out. The implementation of Green Retrofitting is relatively a new concept in developing countries, so that the risks of Green Retrofitting are likely to be greater and more complex than those of conventional projects. This study aims to identify the effect of cost estimation on Green Retrofitting work which is influenced by the dominant risk factors. This research uses linier regression method, through the SPSS application. It is known some of the dominant risks that affect the cost of Green Retrofitting are material scarcity and fluctuations in the price of Green Product’s materials.